|
Market Closed -
Nasdaq
00:00:00 05/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 11.32 USD | +1.89% |
|
+2.63% | -44.40% |
| 08-11 | BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 | MT |
| 08-04 | Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Keros Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,369 | 1,323 | 1,191 | 641.2 | 620.3 | 224.4 | - | - |
| Change | - | -3.39% | -9.94% | -46.17% | -3.27% | -63.82% | - | - |
| Enterprise Value (EV) | 1,369 | 1,323 | 860 | 81.3 | 620.3 | 224.4 | 224.4 | 224.4 |
| Change | - | -3.39% | -34.98% | -90.55% | 662.95% | -63.82% | 0% | 0% |
| P/E | -23.2x | -11.6x | -7.65x | -3.17x | 8.85x | -2.04x | -1.82x | -2.43x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.82x | -0x | 0x | -0.1x | 0.1x |
| Capitalization / Revenue | 68.1x | - | 7,889x | 181x | 2.54x | 14.4x | 16.4x | 5.02x |
| EV / Revenue | 0x | - | 0.01x | 0x | 0x | 14.4x | 16.4x | 5.02x |
| EV / EBITDA | - | - | -0x | -0x | 0x | -2.03x | -2.58x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -1.86x | -1.45x | -1.63x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -2.26x | -1.79x | -1.91x |
| FCF Yield | -4.61% | -5.39% | -10.7% | -25.3% | 17.1% | -44.2% | -55.9% | -52.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.52 | -4.15 | -5.2 | -5 | 2.3 | -5.537 | -6.236 | -4.657 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 20.1 | - | 0.151 | 3.55 | 244.1 | 15.57 | 13.73 | 44.69 |
| EBITDA 1 | - | - | -169.1 | -209.6 | 69.08 | -110.4 | -87.15 | - |
| EBIT 1 | -56.37 | -114.8 | -169.9 | -210.8 | 67.57 | -120.5 | -154.3 | -137.9 |
| Net income 1 | -58.74 | -104.7 | -153 | -187.4 | 87.01 | -110.4 | -147.4 | -133 |
| Net Debt | - | - | -331.1 | -559.9 | - | - | - | - |
| Reference price 2 | 58.51 | 48.02 | 39.76 | 15.83 | 20.36 | 11.32 | 11.32 | 11.32 |
| Nbr of stocks (in thousands) | 23,399 | 27,543 | 29,959 | 40,507 | 30,466 | 19,827 | - | - |
| Announcement Date | 09/03/22 | 03/03/23 | 28/02/24 | 26/02/25 | 04/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.04x | - | - | -.--% | 224M | |
| 20.25x | 7.04x | 14.2x | 1.45% | 67.98B | |
| 36.9x | 9.64x | 29.44x | 0.04% | 64.94B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.85x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.69x | 6.35x | 16.48x | -.--% | 25.74B | |
| 27.41x | 5.13x | 17.06x | -.--% | 20.09B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.16B | |
| 1289.22x | 37.23x | 812.54x | -.--% | 14.92B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 137.59x | 12.23x | 95.53x | 0.18% | 27.93B | |
| Weighted average by Cap. | 81.95x | 10.35x | 51.60x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- KROS Stock
- Valuation Keros Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
